ORIC
Oric Pharmaceuticals, Inc. Health Care Pharmaceutical Preparations Russell 3000
$9.24Close
$910.4MMarket cap
$7.47 – $14.6552-week range
Nov 12, 2026Next report
Highlights
Cautions
- Not in an uptrend 2 of 8 trend conditions
- Lagging the market RS 22 · weaker than 78% of stocks over 12 months
- Far from its high 37% below its 52-week high
- Results soon Nov 12, 2026, in 11 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
37%
1wk
down 29.8%
price change
1mo
down 31.4%
price change
12-month return
down 31%
market up 11% ·
its own down 39%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.4×
price / book
Earnings yield
down 16.5%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 41%
return on equity
Free cash margin
—
-$111.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
11.1%
$1.03 a day · 2×ATR $7.18
RS
22 / 99
vs the universe
Trend
2 / 8
trend template
Relative volume
1.6×
vs 50-day average
Up/down volume
0.89
50 sessions
Implied move
—
no option chain · report Nov 12, 2026
Trend template · 2 of 8
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 38.7% over the year, from 71m to 99m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 3, 2026
Last shock
Oct 26, 2026-32% in one session4.6× volumeon an SEC filing+3% since
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$74.2M | -$78.9M | -$91.8M | -$110.8M | -$142.9M | -$143.0M |
| Net income | -$73.7M | -$78.7M | -$89.1M | -$100.7M | -$127.8M | -$129.5M |
| Earnings per share | — | -$2.07 | -$2.25 | -$1.96 | -$1.83 | -$1.47 |
| Free cash flow | -$45.9M | -$60.5M | -$77.2M | -$86.5M | -$113.8M | -$111.7M |
| Cash | $78.4M | $226.0M | $66.8M | $23.4M | $59.4M | $45.7M |
| Long-term debt | $600,000 | $10.5M | — | — | — | — |
| Shareholders' equity | $289.8M | $273.0M | $222.4M | $224.1M | $243.1M | $384.4M |
| Shares outstanding | 36.67m | 39.43m | 45.09m | 54.87m | 71.02m | 98.53m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 3, 2026 | Quarterly ↗ | Jun 30, 2026 | 34d |
| May 4, 2026 | Quarterly ↗ | Mar 31, 2026 | 34d |
| Feb 23, 2026 | Annual ↗ | Dec 31, 2025 | 54d |
| Nov 13, 2025 | Quarterly ↗ | Sep 30, 2025 | 44d |
| Aug 12, 2025 | Quarterly ↗ | Jun 30, 2025 | 43d |
| May 5, 2025 | Quarterly ↗ | Mar 31, 2025 | 35d |
| Feb 18, 2025 | Annual ↗ | Dec 31, 2024 | 49d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 12, 2024 | Quarterly ↗ | Jun 30, 2024 | 43d |
| May 6, 2024 | Quarterly ↗ | Mar 31, 2024 | 36d |
| Mar 11, 2024 | Annual ↗ | Dec 31, 2023 | 71d |
| Nov 6, 2023 | Quarterly ↗ | Sep 30, 2023 | 37d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 23, 2026 | Regulation FD · Other events ↗ |
| Aug 3, 2026 | Results ↗ |
| Jul 30, 2026 | Director or officer change ↗ |
| Jun 22, 2026 | Director or officer change · Shareholder vote ↗ |
| May 4, 2026 | Results ↗ |
| Mar 31, 2026 | Other events ↗ |
| Feb 23, 2026 | Other events ↗ |
| Feb 23, 2026 | Results ↗ |
| Dec 8, 2025 | Other events ↗ |
| Nov 13, 2025 | Regulation FD ↗ |
| Nov 13, 2025 | Results ↗ |
| Aug 12, 2025 | Results · Restructuring ↗ |